Altre lingue ZYUS Life Sciences Corporation

Azioni

ZYUS

CA9899601095

Mercato chiuso - Toronto S.E. Altri mercati azionari 21:11:34 26/04/2024			Variaz. 5gg	Var. 1 gen.
1,05 ^CAD	+3,96%		+5,00%	+16,67%

01/02	Zyus nomina il Dr. Hance Clarke nel Comitato di Consulenza Clinica	CI
2023	ZYUS Life Sciences Corporation annuncia la sperimentazione clinica di Fase 2 che valuta Trichomylin®? Capsule Softgel per la gestione avanzata del dolore da cancro	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

ZYUS Life Sciences Receives US Patent for Pain Management Drug Candidate	23/04
ZYUS Life Sciences Receives United States Patent No. 11,963,943 Covering Pain Management	23/04
Calian Group and MDA Brief: Calian Says "Strengthens Nuclear Capability" with Acquisition of MDA Ltd. Nuclear Assets	05/03
Calian Group Says Won Contract to Support Clinical Trial for ZYUS Life Sciences' Lead Drug Product Candidate	20/02
Calian Group Brief: Says Won Contract to Support Clinical Trial for ZYUS Life Sciences' Lead Drug Product Candidate	20/02
ZYUS Strengthens Expertise of Clinical Advisory Committee with the Appointment of Dr. Hance Clarke	02/02
ZYUS Life Sciences Appoints Dr. Hance Clarke to Clinical Advisory Committee	01/02
Zyus Appoints Dr. Hance Clarke as Clinical Advisory Committee	01/02
ZYUS Strengthens Leadership Team with Appointment of Vice President of Clinical Research	10/01
ZYUS Life Sciences Corporation Announces Phase 2 Clinical Trial Evaluating Trichomylin Softgel Capsules for Advanced Cancer Pain Management	06/12
ZYUS Life Sciences Corp. Announces Phase 2 Trial Evaluating Trichomylin Softgel Capsules for Advanced Cancer Pain Care	05/12
ZYUS Life Sciences Corporation Announces Phase 2 Clinical Trial Evaluating Trichomylin®? Softgel Capsules for Advanced Cancer Pain Management	05/12
ZYUS Life Sciences Corporation Reports Q3 2023 Results	30/11
ZYUS Life Sciences Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	30/11
ZYUS Life Sciences Corporation Announces Positive Phase I Clinical Trial Results for Trichomylin Softgels	22/11
ZYUS Life Sciences Corp. Brief: Announced "Positive" Phase I Clinical Trial Results for Trichomylin Softgels	21/11
ZYUS Life Sciences Corporation Announces Positive Phase I Clinical Trial Results for Trichomylin® Softgels	21/11
ZYUS Life Sciences Corporation Announces New Director of Investor Relations and Capital Markets	25/10/23
ZYUS Life Sciences Corporation Appoints Tim Miller as Director of Investor Relations and Capital Markets, Effective November 1, 2023	24/10/23
ZYUS Life Sciences Corporation Obtains Health Canada Security Clearance for New Board Member Wayne Brownlee	01/09/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue ZYUS Life Sciences Corporation

Azioni

ZYUS

CA9899601095

Altre lingue

Filtri